SOPHiA GENETICS and Dasa foster a new data-driven medicine era in the fight against cancer   On 23 July, SOPHiA…

New MRI method, developed in Lausanne enhances eye imagery and clears new path for further research   Research from the…

Incyte inaugurates its new European HQ in Morges   In July 2020, the global pharmaceutical company, Incyte inaugurated its new…

Artiria Medical raises CHF 3 million to improve stroke treatment   EPFL spin-off, Artiria Medical, is developing micro-actuated catheters and…

iOnctura raise an additional €5.1 million for their series A funding, reaching a total of €20.1 million   The Geneva-based…

EMBION™ Technologies S.A., hard-tech, disruptive innovator in plant-based bioactives for the nutrition of the future, announces the market launch of PREMBION™. It is the first patented product with complex prebiotic properties for animal nutrition that was created with EMBION’s novel platform technology. The spin-off of the Swiss Federal Institute of Technology in Lausanne (EPFL) accelerates nutrition innovation toward increased functionality and greater affordability. It reduces the time from discovery to commercial production by up to 80%. Market introduction tests are currently underway with leading global corporations in the food, feed and drinks sectors.

Polares Medical Closes a $40M Financing to Complete Pilot Clinical Studies   On 25 June 2020, Polares Medical SA, a…

Unique biosafety laboratory at the University of Bern   On 16 June, the new BSL-3 biosafety laboratory of the University…

CoreMedica Laboratories Inc. provides COVID-19 serology confirmations via a secondary antibody detection method   On 12 June 2020, CoreMedica Laboratories,…

HMCare will launch the production of its HelloMask as of early 2021   For the past two years, the EPFL…

GliaPharm reaches a total of CHF 2 million raised to further its drug development   On 25 May 2020, EPFL…

Bachem supplies key anaesthetic drug to support fight against COVID-19   The Swiss-based company, Bachem, is the world leader in…